ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 327 filers reported holding ROYALTY PHARMA PLC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,786 | -76.8% | 58,095 | -72.8% | 0.17% | -78.4% |
| Q1 2023 | $7,690 | -11.5% | 213,430 | -3.0% | 0.78% | -15.9% |
| Q4 2022 | $8,692 | -99.9% | 219,940 | -3.6% | 0.93% | -10.2% |
| Q3 2022 | $9,171,000 | -5.8% | 228,250 | -1.4% | 1.04% | +3.8% |
| Q2 2022 | $9,734,000 | +8.8% | 231,545 | +0.8% | 1.00% | +41.5% |
| Q1 2022 | $8,949,000 | -1.5% | 229,685 | +0.8% | 0.71% | +7.3% |
| Q4 2021 | $9,083,000 | +8.7% | 227,935 | -1.5% | 0.66% | +6.8% |
| Q3 2021 | $8,359,000 | +17.9% | 231,305 | +33.7% | 0.62% | +26.0% |
| Q2 2021 | $7,092,000 | -5.7% | 173,025 | +0.3% | 0.49% | -15.4% |
| Q1 2021 | $7,523,000 | -13.1% | 172,475 | -0.3% | 0.58% | -18.1% |
| Q4 2020 | $8,657,000 | +33.4% | 172,975 | +12.1% | 0.71% | +12.8% |
| Q3 2020 | $6,489,000 | – | 154,250 | – | 0.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |